Tempus AI vs Labcorp

Side-by-side comparison of AI visibility scores, market position, and capabilities

Labcorp leads in AI visibility (79 vs 58)
Tempus AI logo

Tempus AI

ChallengerHealthcare Tech

Precision Medicine & Diagnostics

AI precision medicine company. NASDAQ: TEM. 2025 revenue $1.27B (+83% YoY). World's largest clinical/molecular data library. Founded 2015, Chicago. 2026 guidance ~$1.59B.

AI VisibilityBeta
Overall Score
C58
Category Rank
#143 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
53
Perplexity
57
Gemini
55

About

Tempus AI is an AI-powered precision medicine company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. The company has built the world's largest library of clinical and molecular data, comprising over 40 million research records including 1.5 million with matched clinical-genomic data. Tempus provides precision medicine services across oncology, cardiology, radiology, and depression through Genomics, Data and Services, and AI Applications product lines.

Full profile
Labcorp logo

Labcorp

LeaderHealthcare Tech

Enterprise

Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
82
Gemini
73

About

Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.

Full profile

AI Visibility Head-to-Head

58
Overall Score
79
#143
Category Rank
#31
74
AI Consensus
68
stable
Trend
stable
53
ChatGPT
74
57
Perplexity
82
55
Gemini
73
63
Claude
85
62
Grok
75

Key Details

Category
Precision Medicine & Diagnostics
Enterprise
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Tempus AI
Precision Medicine & Diagnostics

Integrations

Only Tempus AI
Only Labcorp
Tempus AI is classified as company. Labcorp is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.